Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Capital Expenditures (2022 - 2023)

Spruce Biosciences (SPRB) has disclosed Capital Expenditures for 2 consecutive years, with $7000.0 as the latest value for Q3 2023.

  • On a quarterly basis, Capital Expenditures rose 250.0% to $7000.0 in Q3 2023 year-over-year; TTM through Dec 2024 was $7000.0, a 22.22% decrease, with the full-year FY2023 number at $7000.0, down 12.5% from a year prior.
  • Capital Expenditures was $7000.0 for Q3 2023 at Spruce Biosciences, up from $2000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $7000.0 in Q3 2023 to a low of $2000.0 in Q3 2022.